Generic Drugs
Nova Science Publishers Inc (Verlag)
978-1-61122-071-1 (ISBN)
Brand-name pharmaceutical companies can delay generic competition that lowers prices by agreeing to pay a generic competitor to hold its competing product off the market for a certain period of time. These so-called "pay-for-delay" agreements have arisen as part of patent litigation settlement agreements between brand-name and generic pharmaceutical companies. "Pay-for-delay" agreements are "win-win" for the companies: brand name pharmaceutical prices stay high, and the brand and generic share the benefits of the brand's monopoly profits. Consumers lose, however: they miss out on generic prices that can be as much as 90 percent less than brand prices. For example, brand-name medication that costs $300 per month, might be sold as a generic for as little as $30 per month. This book examines the "pay-for-delay' program and how drug company pay-offs cost consumers billions.
Preface; Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions; "Pay-for-Delay" Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers' Wallets, & Help Pay for Health Care Reform (The $35 Billion Solution); Statement of The Federal Trade Commission, before the Subcommittee on Courts & Competition Policy, Hearing on "Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry: Why Consumers & the Federal Government are Paying Too Much for Prescription Drugs"; Testimony of Heather Bresch, Chief Operating Officer, Mylan, Inc, before the Subcommittee on Courts & Competition Policy, Hearing on "Pay to Delay: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive"; Testimony of Bret M Dickey, Senior Vice President, Compass Lexecon, before the Subcommittee on Courts & Competition Policy, Hearing on "Pay to Delay: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive"; Statement of Guy Donatiello, Endo Pharmaceuticals Inc., before the Subcommittee on Courts & Competition Policy, Hearing on "Pay to Delay: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive"; Statement of William P. (Bill) Kennedy, Co-Owner, Nephron Pharmaceuticals Corporation, before the U.S. House of Representatives, Hearing on "H.R. 1706, the Protecting Consumer Access to Generic Drugs Act of 2009"; Testimony of William Vaughan, Senior Health Analyst, Consumers Union, Non-Profit Publisher of Consumer Reports, before the Subcommittee on Courts & Competition Policy, Hearing on "Pay to Delay: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive"; Index.
| Zusatzinfo | tables & charts |
|---|---|
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 230 x 155 mm |
| Gewicht | 316 g |
| Themenwelt | Medizin / Pharmazie ► Pharmazie |
| Studium ► Querschnittsbereiche ► Prävention / Gesundheitsförderung | |
| Technik | |
| ISBN-10 | 1-61122-071-8 / 1611220718 |
| ISBN-13 | 978-1-61122-071-1 / 9781611220711 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
